Diana Saraceni (Panakès Partners)
July 20, 2021 03:30 AM EDT
Financing

On a mis­sion to sup­port 'un­der­served' Eu­ro­pean star­tups, Panakès Part­ners dips in­to the biotech sec­tor with its lat­est fund

Nicole DeFeudis

Editor

Di­ana Saraceni knows how to put to­geth­er a VC fund. Af­ter co-found­ing Italy-based Panakès Part­ners back in 2015, the man­ag­ing part­ner is now clos­ing the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

Post-Hoc: Biose­cure is dead. Long live Biose­cure? 

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

US spent $450B on drugs last year, CMS says, with new obe­si­ty and di­a­betes drugs adding to to­tal

A service from the Financial Times